Received Jun 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Shingles; This non-serious case was reported by a other health professional via patient support programs and described the occurrence of shingles in a 49-year-old patient who received Men B NVS (Bexsero) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. The patient's past medical history included shingles. Concurrent medical conditions included immunocompromised. On an unknown date, the patient received Bexsero and the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Bexsero and Shingrix, the patient experienced shingles (Verbatim: Shingles). The outcome of the shingles was unknown. It was unknown if the reporter considered the shingles to be related to Bexsero, Bexsero Pre-Filled Syringe Device and Shingrix. It was unknown if the company considered the shingles to be related to Bexsero, Bexsero Pre-Filled Syringe Device and Shingrix. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date:04-JUN-2025 The patient received Shingrix shot and insurance denied coverage due to treatment not deemed to be effective.
Immunocompromised
Medical History/Concurrent Conditions: Shingles